Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) Invested Capital (2016 - 2025)

Historic Invested Capital for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $48.0 million.

  • Harvard Bioscience's Invested Capital fell 5344.54% to $48.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.0 million, marking a year-over-year decrease of 5344.54%. This contributed to the annual value of $100.3 million for FY2024, which is 851.99% down from last year.
  • Per Harvard Bioscience's latest filing, its Invested Capital stood at $48.0 million for Q3 2025, which was down 5344.54% from $50.6 million recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's Invested Capital ranged from a high of $131.7 million in Q4 2021 and a low of $48.0 million during Q3 2025
  • In the last 5 years, Harvard Bioscience's Invested Capital had a median value of $116.8 million in 2023 and averaged $105.6 million.
  • Per our database at Business Quant, Harvard Bioscience's Invested Capital skyrocketed by 564.85% in 2021 and then crashed by 5344.54% in 2025.
  • Harvard Bioscience's Invested Capital (Quarter) stood at $131.7 million in 2021, then fell by 9.63% to $119.0 million in 2022, then decreased by 7.9% to $109.6 million in 2023, then fell by 8.52% to $100.3 million in 2024, then crashed by 52.11% to $48.0 million in 2025.
  • Its Invested Capital stands at $48.0 million for Q3 2025, versus $50.6 million for Q2 2025 and $50.8 million for Q1 2025.